Amarin Corp Plc (AMRN)

[Jt0082]

I think everyone was annoyed when they raised early in 2018 - Q: "Why NOW at this price if you are so confident of R-IT success?"

A from Amarin: "We wanted to be in a strong position post the trial result and focused on raising profile of Vascepa not focused on raising more money from the market under unknown market conditions."

To me... eventhough price they raised was disappointing, I think it was a very very good move in hindsight. A secondary at this point is totally optional. Optional on whether they go it alone or not.

My gut is you wont see a secondary, and if you do, it will be post AHA . My personal view is its most probably a positive signal for AHA they havent done one.